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Martinez-Valbuena et al.1 provide histological evidence of amylin-β amyloid (Aβ) and
amylin-tau cross-seeding in both pancreatic and brain tissues, suggesting a possible
connection in the pathogenesis of Alzheimer’s disease (AD) and type 2 diabetes. They noted
pancreatic amylin-Aβ and amylin-tau deposits in humans with AD in the absence of type-2
diabetes, which the authors interpreted as potential evidence for a role of Aβ and tau tangle
pathology in insulin resistance in these subjects. We suggest an alternative interpretation of
this finding that we base on four key observations: 1, pancreatic β-cells express and process
both the Aβ protein precursor and tau mRNAs2 implying that amylin-Aβ and amylin-tau
inclusions may originate from the pancreas; 2, affected age-groups and clinical trajectories
in type-2 diabetes and late-onset AD generally indicate that diabetes most commonly
precedes AD and is associated with an acceleration of the transition from mild cognitive
impairment to dementia; 3, consistent with this observation and because rodent amylin is
non-amyloidogenic, rodent AD models do not develop type-2 diabetes, whereas pancreatic
expression of amyloid-forming human amylin in non-AD rats causes type-2 diabetes, brain
amylin deposition and behavior deficits3; and 4, the brain region involved in the central
regulation of pancreatic β-cell function (i.e., the hypothalamus)4 is affected by AD
pathology. Consequently, AD may impair central signaling pathways that regulate amylin
secretion leading to pancreatic β-cell dysfunction and impaired clearance of amylin, Aβ and
tau. We therefore posit that the presence of mixed amylin-Aβ or amylin-tau inclusions in the
pancreatic β-cells of patients with AD may reflect an in situ stress response to comorbid
endocrine dysfunction and amylin dyshomeostasis.
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Martinez-Valbuena et al1 highlight the complex mechanisms underlying pancreatic β-cell
dysfunction and linked amylin-Aβ and amylin-tau pathology in type-2 diabetes. Taken
together with published evidence showing the presence of mixed amylin-Aβ pathology in
human AD5, these new data1 provide support for the hypothesis that overexpression and/or
impaired clearance of amyloidogenic proteins (amylin, Aβ, tau) are critical pathological
pathways in both type-2 diabetes and AD. Without excluding possible contributions of Aβ
and tau tangle pathology to the development of type-2 diabetes, our alternative interpretation
only serves to emphasize the need for in vivo studies that can further elucidate the temporal
sequence of amylin- and Aβ-mediated pathological events involving type-2 diabetes and
AD.
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